AstraZeneca reports boost in cancer drug sales

LONDON — Anglo-Swedish drugmaker AstraZeneca is reporting its first quarterly sales in years on the back of new cancer treatments.

The company said Friday that product sales rose 4 percent in the fourth quarter to $5.49 billion, buoyed by new drugs such as bladder cancer treatment Imfinzi, and lymphoma medication Calquence.

It was the first increase since the third quarter of 2014.

AstraZeneca says it expects product sales to increase "in the low single digits" this year.

Despite encouraging news on the sales front, net income fell 29 percent to $1.3 billion. Core operating profit, which excludes restructuring and acquisition-related costs to give a better picture of underlying performance, fell 12 percent to $1.79 billion.

CEO Pascal Soriot says the sales increase shows AstraZeneca is "steadily turning a corner."

You may also interested in

Beer mega merger: what court ruling means for...

Aug 23, 2016

A British court has recommended that two classes of shareholders be created and vote separately on...

Janmaat becomes Watford's 3rd signing in a week

Aug 24, 2016

Netherlands right back Daryl Janmaat has become Watford's third signing in a week after completing...

UK lawmakers urge social media companies to...

Aug 25, 2016

British lawmakers are demanding that social media giants do more to tackle sites that promote...

Antonio in, Barkley out as Allardyce names 1st...

Aug 28, 2016

Sam Allardyce dropped midfielder Ross Barkley and called up uncapped winger Michail Antonio for his...

Global stocks rise as investors weigh future of...

Aug 30, 2016

Global stock markets mostly rose on Tuesday as investors weighed the possibility and timing of...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!